Menopause & Peptides: What the Research Shows

Medically reviewed by Kristi A. Sawicki, Ph.D., Precision Medicine Specialist, member of the Peptide World Medical Advisory Board (August 11, 2026).

This guide covers what the research actually shows, where it is strong, where it is weak, and what honest clinical expectations look like for women considering peptides as part of their menopause management.

Key Takeaways

• Menopause involves a “double hormonal decline”, sex hormones (estrogen, progesterone) AND growth hormone/IGF-1 decline simultaneously. HRT addresses the first; GH secretagogue peptides address the second.
• There are no large randomized controlled trials specifically examining GH secretagogues in peri- or post-menopausal women. The evidence base is mechanistic rationale, general GH peptide data in older adults, smaller studies, and clinical experience.
• GH secretagogues (sermorelin, CJC-1295 + ipamorelin) are most consistently used for menopausal body composition changes, sarcopenia (muscle loss) and visceral fat, and for sleep architecture improvement. These are the best-evidenced applications.
• PT-141 (bremelanotide) is the only FDA-approved peptide specifically for women’s sexual dysfunction, approved for hypoactive sexual desire disorder (HSDD) in premenopausal women.
• Peptides cannot address the estrogen receptor-specific effects of menopause: vasomotor symptoms (hot flashes), vaginal atrophy, and the cardiovascular and bone-protective effects of estrogen. For these, HRT is the appropriate treatment.
• Women with personal or family history of hormone-sensitive cancers require specialist assessment before GH peptides, elevated IGF-1 has theoretical cancer-promotion implications that require individual risk-benefit discussion.

The Double Hormonal Decline of Menopause

One of the most important, and least discussed, aspects of menopause is that it does not involve only the sex hormone decline. The same period of life that produces estrogen and progesterone loss also produces accelerated GH axis decline. GH and IGF-1 already decline with age, and the hormonal changes of menopause, particularly declining estrogen, may further influence the GH/IGF-1 axis, with consequences for body composition, energy, and tissue repair capacity.

The Honest Evidence Position

⚠️ What the Evidence Base Actually Looks Like for Peptides in Menopause

The Endocrine Society states clearly that there is “no definitive evidence that GH or its secretagogues significantly improve functional aging or menopause outcomes in healthy elderly adults.” No large, randomised controlled trial has examined GH secretagogue peptides specifically in peri- or post-menopausal women.

What does exist is: (1) established biology showing parallel GH/IGF-1 decline in women through menopause; (2) general GH peptide data in older adults showing body composition improvements (increased lean mass, decreased fat mass) at the cost of modest side effects; (3) smaller studies and extensive clinical experience in functional medicine settings; and (4) patient-reported outcomes showing better sleep, energy, and body composition.

This is a stronger evidence position than the similar state of many longevity peptides (where even the mechanistic rationale is less clear), but it is meaningfully weaker than the evidence supporting HRT for its primary indications. These are complementary, not competing tools, and in each domain, the evidence base has a different strength.

GH Secretagogues: The Best-Evidenced Category for Menopause

Sermorelin

GHRH analogue, most physiological GH stimulator; most commonly used in women

Sermorelin is a synthetic analogue of natural GHRH, the hormone the hypothalamus uses to signal the pituitary to produce GH. Its short half-life (approximately 20 minutes) means it clears rapidly while stimulating the body’s own GH pulses with longer-lasting effects. It is physiologically the most natural approach to GH axis support, mimicking the body’s own regulatory mechanism.

In the menopausal context, sermorelin is most commonly used for three overlapping applications: body composition support (lean mass preservation, fat reduction), sleep improvement (amplifying the natural nocturnal GH pulse during slow-wave sleep), and skin quality (collagen synthesis via IGF-1). Results typically take 3–6 months to become clearly noticeable. Sermorelin was FDA-approved for childhood GH deficiency (brand name Geref) but was taken off the market for commercial rather than safety reasons and is no longer an approved medicine in the US.^[1]

For women who cannot use HRT: Sermorelin has been positioned specifically as an option for women who want hormonal support but cannot or choose not to use HRT, it is non-androgenic (no virilization risk) and requires no DEA classification, though its effect on the sex hormone axis is not zero: GHRH signaling interacts with LH and FSH, so an indirect influence is possible. It does not address hot flashes, vaginal atrophy, or bone protection, these remain HRT-specific benefits.

CJC-1295 + Ipamorelin

GHRH + GHRP combination, a widely used GH secretagogue stack

The CJC-1295 and ipamorelin combination targets the GH axis through two complementary pathways, CJC-1295 as a GHRH analogue (amplitude of GH pulse) and ipamorelin as a ghrelin receptor agonist (pulse frequency). Together they produce a larger GH stimulus than either alone, with ipamorelin’s selective profile avoiding the cortisol and prolactin elevation seen with older GH secretagogues.

For perimenopausal and menopausal women, the clinical rationale is the same as for all GH secretagogues: addressing the GH/IGF-1 decline that contributes to body composition changes, sleep disruption, and recovery impairment. Women report faster exercise recovery, improved sleep depth, and gradual body composition changes as the primary effects. CJC-1295 without the DAC (drug affinity complex) modification is preferred for sleep applications as it preserves pulsatile GH release.

Skin and Tissue Support: GHK-Cu

GHK-Cu (Copper Peptide)

Topical carrier and signal peptide with decades of mechanistic and preclinical research

GHK-Cu is one of the most extensively studied peptides for skin regeneration, with decades of mechanistic and preclinical research and some human topical data. It is particularly relevant during menopause when the combination of GH decline and estrogen decline produces a rapid loss of skin thickness, collagen, and elasticity. GHK-Cu has substantial mechanistic and preclinical evidence for stimulating collagen synthesis, along with limited human data suggesting improvements in skin density, firmness, and appearance.^[7]

The menopause-specific application is topical GHK-Cu for skin maintenance during the period of accelerated collagen loss. Post-menopausal skin loses collagen faster than any other period, the dual hormonal decline makes this a particularly impactful target. For systemic anti-inflammatory and tissue repair benefits, injectable GHK-Cu is used in some clinical settings, though this evidence base is less developed than the topical data. GHK-Cu is available GRAS-approved in cosmetic formulations and as a compoundable injectable.

Circadian Support: Epitalon

Epitalon

Pineal peptide, melatonin restoration and circadian rhythm support

Epitalon’s primary mechanism in the menopause context is its documented ability to restore melatonin production from the pineal gland, which declines both with age and during the menopausal transition. Melatonin decline contributes to circadian rhythm disruption, which amplifies virtually every menopausal symptom including sleep disruption, mood changes, and cognitive difficulty.

Clinical and animal studies have documented Epitalon restoring more youthful melatonin secretion patterns in elderly subjects and aged primates. For menopausal women with significantly disrupted sleep that is not explained by vasomotor symptoms alone, suggesting circadian disruption as a component, Epitalon represents a mechanistically coherent intervention. The evidence base is modest and primarily from the Khavinson group in Russia, but the specific circadian application has a clearer relevance in the menopausal transition than in many other contexts.

Sexual Function: PT-141 (Bremelanotide)

PT-141 / Bremelanotide

FDA-approved melanocortin receptor agonist for HSDD in premenopausal women

PT-141 is the only peptide with FDA approval specifically for a women’s sexual health indication. It is approved as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It works through melanocortin receptors in the brain, a pathway that influences sexual motivation and desire centrally, without working through the hormonal axis directly.

For menopausal women: PT-141 is FDA-approved for premenopausal HSDD, and its use in postmenopausal women is off-label. For postmenopausal women with low libido driven by estrogen-related vaginal atrophy and discomfort, local vaginal estrogen typically addresses the primary cause more directly. For women whose low desire persists despite adequate hormonal optimisation (HRT + testosterone if appropriate), PT-141 offers a central pathway alternative. The FDA-approved product is a subcutaneous auto-injector used about 45 minutes before anticipated sexual activity; PT-141 has also been administered as a nasal spray in clinical research, though the approved formulation is the injection. Common side effects include nausea (in up to 40% of users), flushing, and transient blood pressure changes.^[2]

BPC-157: A Note of Caution in This Population

BPC-157, Special Consideration for Menopausal Women

Inflammatory burden and joint health, but with specific cautions in this population

Menopause is associated with increased inflammatory burden and joint pain, both estrogen-loss and GH decline contribute to this. BPC-157’s anti-inflammatory and tissue repair mechanisms have theoretical relevance to joint and musculoskeletal symptoms of menopause. However, several specific concerns make BPC-157 more problematic in this population than in younger adults.

The cancer concern: BPC-157’s pro-angiogenic properties (promoting blood vessel formation as part of its healing mechanism) have raised theoretical concerns about tumour vascularisation. No study has shown that BPC-157 causes cancer, and background breast cancer incidence in this age group is not by itself evidence against it. The clearer, better-supported caution is an active or recent cancer diagnosis: in that setting, any pro-angiogenic compound warrants avoidance and specialist guidance.

The regulatory context: BPC-157 is not FDA-approved. The FDA removed it from its compounding Category 2 list in April 2026 after the original nominations were withdrawn, but it is not in any category that would permit legal pharmacy compounding. Its regulatory status makes access through legitimate channels more complex. For menopausal women with inflammatory joint symptoms, anti-inflammatory lifestyle interventions, appropriate HRT (estrogen has anti-inflammatory properties), and if appropriate a consultation about safer tissue-support peptides like GHK-Cu are generally preferable starting points.

What Peptides Can and Cannot Do in Menopause

✓ Where Peptides Add Genuine Value

• Body composition: lean mass preservation and visceral fat reduction through GH/IGF-1 restoration
• Sleep architecture: deep sleep quality via GHRH-SWS pathway (separate from vasomotor sleep disruption)
• Exercise recovery and tissue repair capacity
• Skin collagen and quality (GHK-Cu, strong topical evidence)
• Circadian rhythm and melatonin support (Epitalon)
• Sexual desire through central mechanisms (PT-141, FDA approved for premenopausal HSDD)
• As an adjunct to HRT for women who want additional GH axis support
• As a partial alternative for women who cannot use HRT (specific symptoms only)

✗ What Peptides Cannot Replace

• Hot flashes and night sweats, these require estrogen receptor activation; no peptide addresses this
• Vaginal atrophy and genitourinary symptoms, require local or systemic estrogen
• Bone density protection via estrogen receptor pathways
• Cardiovascular effects of estrogen (lipid profile, endothelial function)
• The progesterone-specific effects on sleep and mood
• The full hormonal restoration that appropriately dosed HRT provides
• First-line treatment for any menopausal symptom where HRT is appropriate and not contraindicated

Cancer History and GH Peptides: The Critical Discussion

⚠️ Essential Consideration for Women with Cancer History

GH secretagogues work by elevating IGF-1. IGF-1 promotes cellular proliferation and survival, which supports muscle, bone, and tissue repair, but means chronically elevated IGF-1 is a potential concern, particularly in the context of malignancy. This raises theoretical concerns for cells undergoing abnormal proliferation (cancer cells). Women over 50 are in the demographic with the highest breast cancer incidence, and epidemiological studies have associated higher IGF-1 levels with modestly increased breast cancer risk.^[8]

This does not mean GH secretagogues cause breast cancer, the evidence does not show this, and the IGF-1 elevations from therapeutic peptide use are typically within physiological ranges. However, for women with a personal history of breast cancer (particularly hormone receptor-positive), a family history suggesting BRCA mutation, or other high breast cancer risk factors, GH secretagogue peptides require explicit specialist discussion and individual risk-benefit assessment before use. This should involve an oncologist or a physician specifically trained in hormone and peptide therapy in this population.

The Non-HRT Path: When Peptides Are the Starting Point

Peptides for Women Who Cannot or Choose Not to Use Systemic HRT

For some women, those with a history of hormone-receptor-positive breast cancer, documented VTE, active liver disease, or strong personal preference against hormonal treatment, systemic HRT is not appropriate or not wanted. These women face the consequences of menopause without access to the most effective treatment.

In this context, peptides offer a partial but meaningful alternative, addressing the GH axis decline that HRT also does not address, while leaving the estrogen-specific effects unaddressed (which cannot be corrected without estrogen). Sermorelin in particular is useful here: it addresses body composition, sleep quality, energy, and recovery through a non-sex-hormone pathway, carries no androgenic risk, and has an established physician prescription pathway. It will not resolve hot flashes or vaginal atrophy, but for the subset of menopausal consequences driven by GH decline, it provides genuine benefit.

Non-systemic local vaginal estrogen remains appropriate for genitourinary symptoms even in many women who cannot use systemic HRT, this should be discussed explicitly with a physician, as many women in this category are not offered it.

The Honest Clinical Summary

Peptides for menopause are at their most rational when they are: (1) built on top of an appropriate HRT foundation where HRT is appropriate, addressing the GH axis that HRT does not; (2) used as a partial alternative only for women who genuinely cannot use HRT, with clear expectation that hot flash relief and bone protection require estrogen; (3) prescribed and monitored by a physician who has assessed individual cancer risk and understands the distinction between mechanistic rationale and established clinical evidence. The hype in this space often outpaces what the evidence supports, which makes honest, evidence-graded guidance especially important here.

Want to understand how peptides might fit into your menopause management?

Our free quiz helps you think through your goals before speaking with a clinician.